- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Somerset Today
By the People, for the People
Triata Capital Boosts Legend Biotech Stake by 50%
Investment firm adds 54,300 shares of biotech company in Q3
Mar. 8, 2026 at 12:34pm
Got story updates? Submit your updates here. ›
Triata Capital Ltd increased its position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) by 50.5% during the third quarter, according to a recent SEC filing. The investment firm now owns 161,800 shares of the biopharmaceutical company, making it one of Legend Biotech's largest institutional investors.
Why it matters
Legend Biotech is a commercial-stage biotech company focused on developing chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Its lead asset, Carvykti, was recently approved for the treatment of relapsed or refractory multiple myeloma. Triata Capital's increased stake suggests the firm sees significant growth potential in Legend Biotech's pipeline and commercialization efforts.
The details
According to the filing, Triata Capital purchased an additional 54,300 shares of Legend Biotech in the third quarter, bringing its total position to 161,800 shares. This represents about 0.09% of the company's outstanding shares and makes Triata one of Legend Biotech's top 15 institutional investors.
- Triata Capital increased its Legend Biotech stake during the third quarter of 2026.
The players
Triata Capital Ltd
An investment management firm that owns a sizable stake in Legend Biotech Corporation.
Legend Biotech Corporation
A commercial-stage biopharmaceutical company focused on developing chimeric antigen receptor T-cell (CAR-T) therapies for oncology, including its lead asset Carvykti for the treatment of relapsed or refractory multiple myeloma.
The takeaway
Triata Capital's increased investment in Legend Biotech suggests the firm sees strong growth potential in the biotech company's pipeline and commercialization efforts around its recently approved multiple myeloma therapy. This could signal positive momentum for Legend Biotech as it looks to expand its CAR-T oncology portfolio.
